{"id":4681,"date":"2018-10-29T15:55:09","date_gmt":"2018-10-29T15:55:09","guid":{"rendered":"https:\/\/blog.kolabtree.com\/?p=4681"},"modified":"2020-11-08T16:48:44","modified_gmt":"2020-11-08T16:48:44","slug":"biosimilars-benefits-challenges-and-future","status":"publish","type":"post","link":"https:\/\/www.kolabtree.com\/blog\/biosimilars-benefits-challenges-and-future\/","title":{"rendered":"Biosimilars: Benefits, Challenges and Future"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_45_1 counter-flat ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" area-label=\"ez-toc-toggle-icon-1\"><label for=\"item-69f3483755d5b\" aria-label=\"Table of Content\"><span style=\"display: flex;align-items: center;width: 35px;height: 30px;justify-content: center;direction:ltr;\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/label><input  type=\"checkbox\" id=\"item-69f3483755d5b\"><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.kolabtree.com\/blog\/biosimilars-benefits-challenges-and-future\/#Biologics\" title=\"Biologics\">Biologics<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.kolabtree.com\/blog\/biosimilars-benefits-challenges-and-future\/#The_Case_for_Biosimilars\" title=\"The Case for Biosimilars\">The Case for Biosimilars<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.kolabtree.com\/blog\/biosimilars-benefits-challenges-and-future\/#Biosimilars_Landscape_in_EU_and_USA\" title=\"Biosimilars: Landscape in EU and USA\">Biosimilars: Landscape in EU and USA<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.kolabtree.com\/blog\/biosimilars-benefits-challenges-and-future\/#Benefits_of_biosimilars\" title=\"Benefits of biosimilars:\">Benefits of biosimilars:<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.kolabtree.com\/blog\/biosimilars-benefits-challenges-and-future\/#Cost_reduction_by_competition\" title=\"Cost reduction by competition\">Cost reduction by competition<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.kolabtree.com\/blog\/biosimilars-benefits-challenges-and-future\/#Enhanced_patient_accessibility\" title=\"Enhanced patient accessibility\">Enhanced patient accessibility<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.kolabtree.com\/blog\/biosimilars-benefits-challenges-and-future\/#Incentive_for_innovation\" title=\"Incentive for innovation\">Incentive for innovation<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.kolabtree.com\/blog\/biosimilars-benefits-challenges-and-future\/#Biosimilars_Challenges\" title=\"Biosimilars: Challenges\">Biosimilars: Challenges<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.kolabtree.com\/blog\/biosimilars-benefits-challenges-and-future\/#Patient_and_prescriber_education\" title=\"Patient and prescriber education\">Patient and prescriber education<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.kolabtree.com\/blog\/biosimilars-benefits-challenges-and-future\/#Extrapolation_issue\" title=\"Extrapolation issue\">Extrapolation issue<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.kolabtree.com\/blog\/biosimilars-benefits-challenges-and-future\/#The_interchangeability_question\" title=\"The interchangeability question\">The interchangeability question<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.kolabtree.com\/blog\/biosimilars-benefits-challenges-and-future\/#Rare_diseases\" title=\"Rare diseases\">Rare diseases<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.kolabtree.com\/blog\/biosimilars-benefits-challenges-and-future\/#The_Future_of_Biologics_and_Biosimilars\" title=\"The Future of Biologics and Biosimilars\">The Future of Biologics and Biosimilars<\/a><\/li><\/ul><\/nav><\/div>\n<p>A biosimilar is a biological medicine that is highly similar to an already approved biological medicine. The biosimilars market is expected to triple in size to $15 billion by 2020, McKinsey\u00a0 predicts. By that alone, we see that these medicines can transform <a href=\"https:\/\/www.kolabtree.com\/blog\/ensuring-reproducibility-in-ai-driven-research-how-freelance-experts-can-help-in-biotech-and-healthcare\/\">healthcare<\/a>. A <a href=\"http:\/\/biosimilarscouncil.org\/wp-content\/uploads\/2017\/06\/Biosimilars-Myths-v-Facts-Infographic_FINAL-6-5-17-1.pdf\">report<\/a> by the Biosimilars Council (2018) predicts that biosimilars could save costs of up to $250 billion over the next decade. Can these products improve patient access for those depending on biologic treatments? What are the challenges and opportunities? This includes benefits of biosimilars:<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Biologics\"><\/span>Biologics<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/www.fda.gov\/aboutfda\/centersoffices\/officeofmedicalproductsandtobacco\/cber\/ucm133077.htm\">Biologics<\/a> are biological molecules, sourced from living organisms, used to diagnose, treat and cure many chronic and disabling diseases. The typically large and complex biological molecules \u2014including hormones and monoclonal antibodies\u2014 are manufactured from microorganisms, plant or animal cells using biotechnology. The natural variability within the host organism, results in variability between the various batches of the active biological molecule being produced. Usually, these variabilities are minimal and do not change the biological function. Today, biologics offer one of the most cutting-edge technology for clinical prognoses of many diseases. The therapeutic potential of these molecules ranges from diabetes to autoimmune diseases to cancers. A major drawback of biologics, despite their high demand, is the accompanying excessive cost -a major barrier for patients. Knowing the benefits of biosimilars is highly necessary.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"The_Case_for_Biosimilars\"><\/span>The Case for Biosimilars<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The consumer cost burden could seemingly be lowered by a second category of biologics, called <a href=\"https:\/\/en.wikipedia.org\/wiki\/Biosimilar\"><strong>Biosimilars<\/strong><\/a>. Biosimilars are <a href=\"https:\/\/www.kolabtree.com\/find-an-expert\/subject\/Molecular-Biology?utm_source=Blog&amp;utm_medium=pPost&amp;utm_campaign=Biosimilars\">biological molecules<\/a> that are <em>\u201chighly similar to an already approved reference biological medicine\u201d<\/em>. To qualify as a biosimilar, a molecule must demonstrate equivalent properties in terms of the <em>\u201cstructure, biological activity and efficacy, safety and immunogenicity profile\u201d<\/em>, to the original reference molecule. Like biologics, biosimilars are also manufactured biologically. Thus, the process is naturally variable, resulting in an inherent variability from the reference medicine. These variations render the characterization and the regulatory approval, a challenging task. However, if these variations can be proven to not affect the clinical safety and efficacy, the biosimilar would be considered for approval by the regulatory agencies.<\/p>\n<p>A reference biologics molecule must go through a \u201cstandalone\u201d application containing all data, including <a href=\"https:\/\/www.kolabtree.com\/find-an-expert\/subject\/Clinical-Trials?utm_source=Blog&amp;utm_medium=Post&amp;utm_campaign=Biosimilars\">clinical trials<\/a> demonstrating its safety and effectiveness. When the patent on an original biological medicine expires, other competing companies can apply for marketing approvals for a corresponding biosimilar product. The ultimate goal of a biosimilar development program is to prove \u201cbio-similarity\u201d with the reference drug, rather than establish a standalone safety or efficacy profile. Thus, instead of going through a conventional clinical trial, the biosimilar undergoes a comparative clinical trial to prove a lack of clinical difference from the reference molecule. The biosimilar molecule can piggyback on the safety and efficacy knowledge gathered from the years of usage of the reference molecule.<\/p>\n<p>From a regulatory standpoint, the biosimilar development program need not repeat the entire clinical development program as the original reference biologics molecule. This advantage reduces the costs incurred by both: the manufacturers as well as the consumers. Moreover, it saves a lot of volunteers and patients from engaging in unnecessary trials. Overall, the approval pathway for biosimilars is much more streamlined, simpler and cheaper than the branded original biologics. Consequently, biosimilars enable patients to access medical innovations sooner and cheaper, without compromising on the efficacy or safety. A comprehensive <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0305737216300172\">list<\/a> of biosimilars that are FDA and or EMA approved can be found <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6172013\/table\/t1-dic-7-212543\/?report=objectonly\">here<\/a>.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Biosimilars_Landscape_in_EU_and_USA\"><\/span>Biosimilars: Landscape in EU and USA<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The European Medicines Agency (EMA) pioneered a dedicated route for approval of biosimilars in the European Union (EU) and approved the first biosimilar (<a href=\"https:\/\/www.omnitrope.com\/about\/about-omnitrope\/\">Omnitrope<\/a>) in 2006. Currently, EU is the most mature market for biosimilars, worldwide. In fact, the regulations put in place by EU have set the tone for developing biosimilars in rest of the world. <strong>As of March 2018, there are over 40 EU commission approved biosimilars.<\/strong> This number is only expected to go further up with the continuously expanding pipeline of biosimilars up for review by the EMA. In the last decade, the EU healthcare systems have observed a visible advantage with the competition in the biosimilars market. The EU biosimilar market has been projected to grow close to $4 billion by end of 2018.<\/p>\n<p>In contrast, the biosimilar market in USA is still fairly flat and slowly emerging as the regulatory guidelines are being set in place. The Food and Drug Agency (FDA) approved the first biosimilar only in 2015 (<a href=\"http:\/\/chemocare.com\/chemotherapy\/drug-info\/filgrastim.aspx\">Filgrastim<\/a>). <strong>As of July 2018, there were only <a href=\"https:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/howdrugsaredevelopedandapproved\/approvalapplications\/therapeuticbiologicapplications\/biosimilars\/ucm580432.htm\">12 FDA approved biosimilars<\/a> in the market.<\/strong> Undoubtedly, USA is a critical <a href=\"https:\/\/www.rdmag.com\/article\/2016\/04\/us-biosimilar-market-2016\">market for biosimilars<\/a>. However, many unpredictable factors, including ongoing litigations around patent disputes amongst the innovators, can extend the time-to market. According to RAND Corporation, biosimilars could cut the U.S. health system costs on biologics by about <a href=\"https:\/\/www.rand.org\/content\/dam\/rand\/pubs\/perspectives\/PE200\/PE264\/RAND_PE264.pdf\">$54\u00a0billion<\/a> in the coming decade. Let us now see the benefits of biosimilars.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Benefits_of_biosimilars\"><\/span>Benefits of biosimilars:<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>\n<h3><span class=\"ez-toc-section\" id=\"Cost_reduction_by_competition\"><\/span>Cost reduction by competition<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<\/li>\n<\/ul>\n<p>Biologic medicines can be really expensive. For example, a biologic cancer drug may cost hundreds and thousands of dollars per patient annually. Having multiple biosimilars in the market will break the reference drug monopoly and help bring down the costs.<\/p>\n<ul>\n<li>\n<h3><span class=\"ez-toc-section\" id=\"Enhanced_patient_accessibility\"><\/span>Enhanced patient accessibility<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<\/li>\n<\/ul>\n<p>With more biosimilars in circulation, more patients worldwide can have access to these treatment options.<\/p>\n<ul>\n<li>\n<h3><span class=\"ez-toc-section\" id=\"Incentive_for_innovation\"><\/span>Incentive for innovation<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<\/li>\n<\/ul>\n<p>Biosimilars cannot be marketed until the patent on reference medicine expires. Having innovative, patentable new biologic products maybe necessary to maintain a large marketshare hold, in the wake of expiring patents. Thus, pharmaceutical companies would be encouraged to invest more into cutting edge R&amp;D sectors to foster innovation<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Biosimilars_Challenges\"><\/span>Biosimilars: Challenges<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Despite their affordability, biosimilars face numerous challenges in finding acceptance. Some of the ongoing challenges include:<\/p>\n<ul>\n<li>\n<h3><span class=\"ez-toc-section\" id=\"Patient_and_prescriber_education\"><\/span>Patient and prescriber education<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<\/li>\n<\/ul>\n<p>Though biosimilars have been around for over a decade in EU, they are still a novelty for those outside this sector. According to a <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4889091\/\">survey in 2014<\/a>, almost 30% of people living with a diagnosis said that their medicinal choice was highly influenced by the drug manufacturer\u2019s identity. Mass education is needed in both the health sector as well as the pharmaceutical industry. Prescribers may see biosimilars as extra work: review clinical data, discuss substitution with pharmacists, and so forth. The situation is further complicated by the agreeability of insurers to mandate the switch to biosimilars. The <a href=\"https:\/\/www.kolabtree.com\/find-an-expert\/subject\/Physics?utm_source=Blog&amp;utm_medium=Post&amp;utm_campaign=Biosimilars\">physicians<\/a>,<a href=\"https:\/\/www.kolabtree.com\/find-an-expert\/subject\/pharmacology?utm_source=Blog&amp;utm_medium=Post&amp;utm_campaign=Biosimilars\"> pharmacist<\/a> and patients, all need to be enlightened and subsequently, convinced of the benefits of switching to biosimilars.<\/p>\n<ul>\n<li>\n<h3><span class=\"ez-toc-section\" id=\"Extrapolation_issue\"><\/span>Extrapolation issue<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4894513\/\">Extrapolation<\/a> is \u201cThe process of granting a clinical indication to a medication without its own or new clinical safety and efficacy studies to support that indication\u201d. Whether biosimilars can be prescribed for off-label indications, that are okayed for the reference drug, is a grey area. Appropriate guidelines must be set in place for these indications. If not, hospitals and pharmacies will be forced to carry both the reference molecule as well as the biosimilar counterpart; nullifying the cost benefits from prescribing the biosimilar.<\/p>\n<ul>\n<li>\n<h3><span class=\"ez-toc-section\" id=\"The_interchangeability_question\"><\/span>The interchangeability question<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<\/li>\n<\/ul>\n<p>Interchangeability indicates whether switching back and forth between two products does not influence the efficacy or safety when compared to each product alone. While there are some guidelines in place to determine this, there is uncertainty, prevalent at local prescriber and pharmacy levels. Whether a pharmacist can \u201csubstitute\u201d a reference molecule with an interchangeable biosimilar or vice versa, without an explicit prescription, is another avenue seeking reconciliation.<\/p>\n<ul>\n<li>\n<h3><span class=\"ez-toc-section\" id=\"Rare_diseases\"><\/span>Rare diseases<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<\/li>\n<\/ul>\n<p>Rare disease treatments often utilize \u201corphan drugs\u201d that are associated with high costs. While there are biosimilars being developed for these orphan drugs, they face many practical hurdles. First, it is difficult to obtain a large enough, non-heterogeneous population for phase I and III trials. Furthermore, the cost of manufacturing enough batches of the biosimilar to run batch-to-batch variability studies to build extensive comparability data, can be disproportionately high.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"The_Future_of_Biologics_and_Biosimilars\"><\/span>The Future of Biologics and Biosimilars<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The biosimilars industry and its regulation has grown in leaps and bounds in the last decade. With some of the most prescribed biologics facing patent expiration in near future, the biosimilars market is poised for added growth. The market competition driven by biosimilars can pose threat to the monopoly of the brand pharmaceutical industry. Often, the pharma giants are seen to be thwarting the biosimilars companies in the web of intellectual property rights. In the coming years, the regulatory authorities need to provide a more tangible framework to address some grey areas in the marketing and prescription of biosimilars. This, accompanied with practitioner\/consumer education, new development and commercial models can set the stage for creating new blockbuster biosimilars. Here were the benefits of biosimilars.<\/p>\n<p>&#8212;-<br \/>\n<b>Need help with consulting from <a href=\"https:\/\/www.kolabtree.com\/find-an-expert\/subject\/bioinformatics?utm_source=Blog&amp;utm_medium=Post&amp;utm_campaign=Biosimilars\">Bioinformatician<\/a>?\u00a0Hire a\u00a0<a href=\"https:\/\/www.kolabtree.com\/find-an-expert\/subject\/bioinformatics?utm_source=Blog&amp;utm_medium=Post&amp;utm_campaign=Biosimilars\">freelance Bioinformatics<\/a>\u00a0expert<\/b><b>\u00a0on Kolabtree. It\u2019s free to post your project and get quotes.<\/b><\/p>\n<p>Related Experts:<br \/>\n<a href=\"https:\/\/www.kolabtree.com\/find-an-expert\/subject\/bioinformatics?utm_source=Blog&amp;utm_medium=Post&amp;utm_campaign=Biosimilars\">Hire a Bioinformatician<\/a>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0<a href=\"https:\/\/www.kolabtree.com\/find-an-expert\/subject\/Molecular-Biology?utm_source=Blog&amp;utm_medium=Post&amp;utm_campaign=Biosimilars\">Hire a Molecular Biologist\u00a0<\/a>\u00a0\u00a0 \u00a0\u00a0<a href=\"https:\/\/www.kolabtree.com\/find-an-expert\/subject\/biostatistics?utm_source=Blog&amp;utm_medium=Post&amp;utm_campaign=Biosimilars\">Hire a Biostatistician<\/a><\/p>\n<p>Need to consult a freelance scientist? Choose from 10,000+ experts on <a href=\"https:\/\/www.kolabtree.com\/?utm_source=Blog&amp;utm_medium=Post&amp;utm_campaign=Biosimilars\">Kolabtree<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A biosimilar is a biological medicine that is highly similar to an already approved biological medicine. The biosimilars market is expected to triple in size to $15 billion by 2020, McKinsey\u00a0 predicts. By that alone, we see that these medicines can transform healthcare. A report by the Biosimilars Council (2018) predicts that biosimilars could save<\/p>\n<div class=\"read-more\"><a href=\"https:\/\/www.kolabtree.com\/blog\/biosimilars-benefits-challenges-and-future\/\" title=\"Read More\">Read More<\/a><\/div>\n","protected":false},"author":43,"featured_media":4695,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[442,443,435],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.1 (Yoast SEO v20.1) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Biosimilars: Benefits, Challenges and Future - The Kolabtree Blog<\/title>\n<meta name=\"description\" content=\"The biosimilars market is expected to triple in size to $15 billion by 2020. Let&#039;s look at benefits of biosimilars.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.kolabtree.com\/blog\/biosimilars-benefits-challenges-and-future\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biosimilars: Benefits, Challenges and Future\" \/>\n<meta property=\"og:description\" content=\"The biosimilars market is expected to triple in size to $15 billion by 2020. Let&#039;s look at benefits of biosimilars.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.kolabtree.com\/blog\/biosimilars-benefits-challenges-and-future\/\" \/>\n<meta property=\"og:site_name\" content=\"The Kolabtree Blog\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kolabtree\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-29T15:55:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-11-08T16:48:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.kolabtree.com\/blog\/wp-content\/uploads\/2018\/10\/syringe-1884784_1280.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Maya Raghunandan\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@kolabtree\" \/>\n<meta name=\"twitter:site\" content=\"@kolabtree\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Maya Raghunandan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biosimilars: Benefits, Challenges and Future - The Kolabtree Blog","description":"The biosimilars market is expected to triple in size to $15 billion by 2020. Let's look at benefits of biosimilars.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.kolabtree.com\/blog\/biosimilars-benefits-challenges-and-future\/","og_locale":"en_US","og_type":"article","og_title":"Biosimilars: Benefits, Challenges and Future","og_description":"The biosimilars market is expected to triple in size to $15 billion by 2020. Let's look at benefits of biosimilars.","og_url":"https:\/\/www.kolabtree.com\/blog\/biosimilars-benefits-challenges-and-future\/","og_site_name":"The Kolabtree Blog","article_publisher":"https:\/\/www.facebook.com\/kolabtree","article_published_time":"2018-10-29T15:55:09+00:00","article_modified_time":"2020-11-08T16:48:44+00:00","og_image":[{"width":1280,"height":768,"url":"https:\/\/www.kolabtree.com\/blog\/wp-content\/uploads\/2018\/10\/syringe-1884784_1280.jpg","type":"image\/jpeg"}],"author":"Maya Raghunandan","twitter_card":"summary_large_image","twitter_creator":"@kolabtree","twitter_site":"@kolabtree","twitter_misc":{"Written by":"Maya Raghunandan","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.kolabtree.com\/blog\/de\/biosimilars-benefits-challenges-and-future\/#article","isPartOf":{"@id":"https:\/\/www.kolabtree.com\/blog\/de\/biosimilars-benefits-challenges-and-future\/"},"author":{"name":"Maya Raghunandan","@id":"https:\/\/www.kolabtree.com\/blog\/#\/schema\/person\/643e6748c2076c93e7b934950f2240c8"},"headline":"Biosimilars: Benefits, Challenges and Future","datePublished":"2018-10-29T15:55:09+00:00","dateModified":"2020-11-08T16:48:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.kolabtree.com\/blog\/de\/biosimilars-benefits-challenges-and-future\/"},"wordCount":1455,"commentCount":0,"publisher":{"@id":"https:\/\/www.kolabtree.com\/blog\/#organization"},"articleSection":["Biotechnology","Healthcare","Research"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.kolabtree.com\/blog\/de\/biosimilars-benefits-challenges-and-future\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.kolabtree.com\/blog\/de\/biosimilars-benefits-challenges-and-future\/","url":"https:\/\/www.kolabtree.com\/blog\/de\/biosimilars-benefits-challenges-and-future\/","name":"Biosimilars: Benefits, Challenges and Future - The Kolabtree Blog","isPartOf":{"@id":"https:\/\/www.kolabtree.com\/blog\/#website"},"datePublished":"2018-10-29T15:55:09+00:00","dateModified":"2020-11-08T16:48:44+00:00","description":"The biosimilars market is expected to triple in size to $15 billion by 2020. Let's look at benefits of biosimilars.","breadcrumb":{"@id":"https:\/\/www.kolabtree.com\/blog\/de\/biosimilars-benefits-challenges-and-future\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.kolabtree.com\/blog\/de\/biosimilars-benefits-challenges-and-future\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.kolabtree.com\/blog\/de\/biosimilars-benefits-challenges-and-future\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.kolabtree.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Biosimilars: Benefits, Challenges and Future"}]},{"@type":"WebSite","@id":"https:\/\/www.kolabtree.com\/blog\/#website","url":"https:\/\/www.kolabtree.com\/blog\/","name":"The Kolabtree Blog","description":"Expert Views on Science, Innovation and Product Development","publisher":{"@id":"https:\/\/www.kolabtree.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.kolabtree.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.kolabtree.com\/blog\/#organization","name":"Kolabtree","url":"https:\/\/www.kolabtree.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.kolabtree.com\/blog\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Kolabtree"},"image":{"@id":"https:\/\/www.kolabtree.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kolabtree","https:\/\/twitter.com\/kolabtree","https:\/\/instagram.com\/kolabtree","https:\/\/www.linkedin.com\/company\/kolabtree","https:\/\/en.m.wikipedia.org\/wiki\/Kolabtree"]},{"@type":"Person","@id":"https:\/\/www.kolabtree.com\/blog\/#\/schema\/person\/643e6748c2076c93e7b934950f2240c8","name":"Maya Raghunandan","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.kolabtree.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/352853843bae23d680d298f0a24858ef?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/352853843bae23d680d298f0a24858ef?s=96&d=mm&r=g","caption":"Maya Raghunandan"},"description":"Maya Raghunandan obtained her Ph.D in Biochemistry and Molecular Biology from the University of Minnesota, Twin cities, USA. Currently, she is a cancer biology scientist at Universit\u00e9 Catholique de Louvain, Brussels, Belgium. In her spare time, she writes about cool science discoveries in her jargon-free blog http:\/\/www.sciencesnippets.org\/. Because, science doesn\u2019t have to sound complicated. Instead, it must be comprehensible for everyone.","url":"https:\/\/www.kolabtree.com\/blog\/author\/mayanandan\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/posts\/4681"}],"collection":[{"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/users\/43"}],"replies":[{"embeddable":true,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/comments?post=4681"}],"version-history":[{"count":9,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/posts\/4681\/revisions"}],"predecessor-version":[{"id":8507,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/posts\/4681\/revisions\/8507"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/media\/4695"}],"wp:attachment":[{"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/media?parent=4681"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/categories?post=4681"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.kolabtree.com\/blog\/wp-json\/wp\/v2\/tags?post=4681"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}